NCT06063850RecruitingPhase 1/2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 1 Sept 2023
- Start date
- 12 Jun 2024
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- UniQure Biopharma B.V.
- Diseases
- Epilepsy
- NCT number
- NCT06063850
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 12
- From 12 Jun 2024 to the primary completion date, 30 Nov 2026
- 18 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Implanted devices that would contraindicate MRI; MRI-compatible devices must be implanted ≥3 months prior to Screening (vagus nerve stimulation devices will be up to discretion of the Investigator).
- Any other contraindications to general anesthesia, surgery, or intra-operative magnetic resonance imaging (MRI).
- Previous major disease-unrelated neurosurgical intervention due to intracranial tumor, trauma, or bleeding and/or history of previous intracranial surgery for treatment of epileptic seizures, not including diagnostic stereo-EEG.
- Status epilepticus within the year prior to Screening.
Other illness
- Bilateral or multifocal epilepsy; or inability to confidently lateralize seizure onset.
- Dementia or other progressive neurological disorders and progressive brain lesions.
Lab values
- Medications that could confound clinical (e.g., antipsychotic medication and anti-viral therapy) and laboratory evaluations or could affect a participant's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule.
Other
- MRI evidence of epileptogenic, extra-temporal lesions, or dual temporal lobe pathology.
Who the study is looking for
- Diagnosis of unilateral refractory MTLE
- History of seizures with an average of ≥ 2 documented focal impaired awareness seizures or focal to bilateral tonic-clonic seizures per 30-day period over the 3 month Retrospective Period.
- On a stable type and dose regimen of up to a maximum of 4 approved Anti Seizure Drugs for at least 1 month prior to the Retrospective Period.
- Confirmed unilateral hippocampal pathology and concordant unilateral seizure focus
- No evidence of focal neurocognitive dysfunction, inconsistent with disease pathology- related MRI and/or (18F)FDG-PET findings.
- Women of childbearing potential (WOCBP) and fertile male subjects must be willing and able to use highly effective methods of birth control consistently and correctly throughout the study.
- For WOCBP only: Negative pregnancy test.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (18)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baylor Scott & White Medical Center Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
| Johns Hopkins School of Medicine Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| Midatlantic Epilepsy and Sleep Center Coordinator of this site? Confirm its status | Bethesda | United States | Completed |
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Ohio State University Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
| Corewell Health Coordinator of this site? Confirm its status | Grand Rapids | United States | Recruiting |
| Northeast Regional Epilepsy Group Coordinator of this site? Confirm its status | Hackensack | United States | Recruiting |
| Mayo Clinic Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Recruiting |
| Kansas University Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| Dartmouth Hitchcock Medical Center Coordinator of this site? Confirm its status | Lebanon | United States | Recruiting |
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| Robert Wood Johnson Hospital Coordinator of this site? Confirm its status | New Brunswick | United States | Recruiting |
| Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Completed |
| Hospital of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Mayo Clinic - Arizona Coordinator of this site? Confirm its status | Phoenix | United States | Recruiting |
| Allegheny Health Network Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.